Last checked at 17 Jul 2015 12:01
Proteome Sciences plc
("Proteome Sciences" or the "Company")
AGM Statement
17th July, 2015. Our core businesses are performing well and the big increase in demand recently reported in biomarker services continues to grow with four further SysQuant® contracts secured since the preliminary results at the end of May. With our facilities running at full capacity in 2015 the process is underway to add further mass spectrometry equipment and output in the second half of the year to satisfy this demand and to significantly increase the scale of the biomarker services division.
We are very pleased to be selected to make 3 oral presentations at the Alzheimer's Association International Conference (AAIC) in Washington DC later this week including SysQuant® and TMT calibrator™ data and results in AD where we will be continuing discussions with prospective licensees for our CK1d compounds.
With the current buoyant background and a good pipeline with excellent prospects the directors expect to see strong growth in revenue and news flow into 2016.
- Ends -
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | |
Dr. Ian Pike, Chief Operating Officer | Tel: +44 (0)1932 865065 |
Geoff Ellis, Finance Director | |
Nominated Adviser | |
Cenkos | |
Mark Connelly/Callum Davidson finnCap Geoff Nash | Tel: +44 (0)20 7397 8900
Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.